Johnson & Johnson (NYSE: JNJ) Received FDA Approval Wednesday August 26, 2026 for Imaavy (Nipocalimab), an Anti-Neonatal Fc Receptor (FcRn) Monoclonal Antibody Administered as Subcutaneous Injection, for the Treatment of Warm Autoimmune Hemolytic Anemia (wAIHA) in Adults and Pediatric Patients Aged 12 and Older; wAIHA Is a Rare Autoimmune Disease in Which Autoantibodies (Primarily IgG) Bind Red Blood Cells at Body Temperature and Trigger Complement- and Macrophage-Mediated Red Blood Cell Destruction, Causing Fatigue, Jaundice, and in Severe Cases Life-Threatening Anemia; The Imaavy Approval Extends the Anti-FcRn Therapeutic Category That Argenx Pioneered With Vyvgart (Efgartigimod Alfa) Into a New Autoimmune Indication Beyond Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
Johnson & Johnson (NYSE: JNJ) received FDA approval Wednesday August 26, 2026 for Imaavy (nipocalimab), an anti-neonatal Fc receptor (FcRn) monoclonal antibody administered as subcutaneous injection, for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 and older. Disease context: wAIHA is a rare autoimmune disease in which autoantibodies (primarily IgG) bind red blood cells at body temperature and trigger complement- and macrophage-mediated red blood cell destruction, causing fatigue, jaundice, splenomegaly, and in severe cases life-threatening anemia. Prior treatment has relied on corticosteroids, rituximab (an anti-CD20 monoclonal antibody), splenectomy, and other immunosuppressants, all with substantial side effects and variable efficacy. Nipocalimab mechanism: blocks the neonatal Fc receptor (FcRn) that normally rescues IgG antibodies from degradation; blocking FcRn accelerates IgG catabolism and reduces the pathogenic IgG autoantibody burden that drives wAIHA. The Imaavy approval extends the anti-FcRn therapeutic category that argenx pioneered with Vyvgart (efgartigimod alfa, IV and SC formulations) into a new autoimmune indication beyond the currently-approved indications of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The FcRn category is a growing modality with multiple companies pursuing autoimmune indications; J&J's Imaavy is now approved for wAIHA and separately in myasthenia gravis, positioning as a direct competitor to argenx's Vyvgart franchise. Approval was supported by Phase 3 clinical data documenting substantial improvements in hemoglobin levels and transfusion-independence rates compared to placebo.